Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Allogene Therapeutics, Inc. - Common Stock
(NQ:
ALLO
)
1.468
-0.032 (-2.10%)
Delayed Quote
Updated: 2:24 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allogene Therapeutics, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
10 Analysts Have This to Say About Allogene Therapeutics
↗
March 21, 2023
Via
Benzinga
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
March 14, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
March 08, 2023
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Via
News Direct
Topics
Economy
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
March 08, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Topics
Economy
Allogene Therapeutics's Return On Capital Employed Insights
↗
March 03, 2023
Via
Benzinga
What 10 Analyst Ratings Have To Say About Allogene Therapeutics
↗
March 02, 2023
Via
Benzinga
5 Analysts Have This to Say About Allogene Therapeutics
↗
January 24, 2023
Via
Benzinga
Expert Ratings for Allogene Therapeutics
↗
January 06, 2023
Via
Benzinga
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
↗
March 07, 2023
Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics.
Via
Benzinga
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
March 02, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
March 01, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 28, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
February 21, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Short Squeezes Have Returned in 2023 -- Here's Your Playbook
↗
February 08, 2023
We haven't seen moves like these in a couple of years, so here's what investors should know.
Via
The Motley Fool
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
February 01, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
January 25, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Why Allogene Therapeutics Shares Are Seeing Blue Skies Today
↗
January 24, 2023
Allogene Therapeutics Inc (NASDAQ: ALLO) shares are trading higher by 13.1% to $7.76 Tuesday morning after the company announced data from its Phase 1 UNIVERSAL trial of ALLO-715 has been published in...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023
↗
January 24, 2023
Via
Benzinga
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
January 24, 2023
ALLO-715 is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety, Efficacy and Durability with Off-the-Shelf Convenience in Multiple Myeloma
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Amazon To Rally Over 28%? Here Are 10 Other Analyst Forecasts For Tuesday
↗
January 24, 2023
Citigroup raised the price target for AT&T Inc. (NYSE: T) from $20 to $22. Citigroup analyst Michael Rollins maintained a Buy rating. AT&T shares fell 1% to $18.91 in pre-market trading.
Via
Benzinga
Yext, 1-800-Flowers.com And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
↗
January 24, 2023
U.S. stock futures traded slightly lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
January 17, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
WWE, AMTD Digital And Some Other Big Stocks Moving Higher In Friday's Pre-Market Session
↗
January 06, 2023
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. AMTD Digital Inc. (NYSE: HKD) shares surged 118.8% to $65.54 in pre-market...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
↗
January 06, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
↗
January 05, 2023
On Thursday, 63 companies set new 52-week lows.
Via
Benzinga
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
↗
January 05, 2023
Via
Benzinga
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
January 03, 2023
Cell Therapy Veteran and Former Kite Pharma Clinical Leader to Head Development of Expanding Portfolio of Allogeneic CAR T Product Candidates
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
↗
December 22, 2022
Crispr and Vertex are working toward the first submissions for a CRISPR-based product.
Via
Investor's Business Daily
Stocks That Hit 52-Week Lows On Friday
↗
December 23, 2022
OnFriday, 143 stocks hit new 52-week lows.
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
